AIMS: Statins are highly effective in reducing major adverse clinical events, but the direct effects on coronary plaque composition remain debatable. Our aim was to mechanistically evaluate the treatment effect of high-intensity statin therapy on compositional coronary plaque changes. METHODS AND RESULTS: The third Integrated Biomarker and Imaging Study (IBIS-3) was a prospective, investigator-initiated, single-centre study. Serial radiofrequency intravascular ultrasound (RF-IVUS) measurements of a predefined non-stenotic segment in a non-culprit coronary artery were performed to evaluate the effect of rosuvastatin (intended dose: 40 mg daily) on necrotic core (NC) volume in patients with stable angina or acute coronary syndrome. Changes in lipid core burden index (LCBI) were evaluated through serial near-infrared spectroscopy (NIRS) imaging in a subset. Serial RF-IVUS (and NIRS) data of a median segment of 41 mm (interquartile range: 32 to 49 mm) were complete in 164 (103) patients. Follow-up measurements were performed at six and 12 months in 30 (26) and 134 (77) patients, respectively. Mean levels of low-density lipoprotein cholesterol decreased by 30%, from 2.49 mmol/l to 1.73 mmol/l at the end of follow-up. High-dose rosuvastatin therapy resulted in a non-significant change of -1.4 mm3 (95% CI: -3.0, 0.1) in NC volume during follow-up (p=0.074). The change in NC percentage of total plaque volume was -1.4% (95% CI: -2.4 to -0.4; p=0.006). A neutral effect was also observed on LCBI. Indications of significant regression of NC volume and LCBI in the highest baseline quartiles were observed, which should cautiously be regarded as hypothesis-generating. CONCLUSIONS: High-intensity rosuvastatin therapy during one year resulted in a neutral effect on NC and LCBI within non-stenotic, non-culprit coronary segments with a relatively low atheroma burden. This study has been registered in The Netherlands Trial Register (NTR) nr. 2872.
AIMS: Statins are highly effective in reducing major adverse clinical events, but the direct effects on coronary plaque composition remain debatable. Our aim was to mechanistically evaluate the treatment effect of high-intensity statin therapy on compositional coronary plaque changes. METHODS AND RESULTS: The third Integrated Biomarker and Imaging Study (IBIS-3) was a prospective, investigator-initiated, single-centre study. Serial radiofrequency intravascular ultrasound (RF-IVUS) measurements of a predefined non-stenotic segment in a non-culprit coronary artery were performed to evaluate the effect of rosuvastatin (intended dose: 40 mg daily) on necrotic core (NC) volume in patients with stable angina or acute coronary syndrome. Changes in lipid core burden index (LCBI) were evaluated through serial near-infrared spectroscopy (NIRS) imaging in a subset. Serial RF-IVUS (and NIRS) data of a median segment of 41 mm (interquartile range: 32 to 49 mm) were complete in 164 (103) patients. Follow-up measurements were performed at six and 12 months in 30 (26) and 134 (77) patients, respectively. Mean levels of low-density lipoprotein cholesterol decreased by 30%, from 2.49 mmol/l to 1.73 mmol/l at the end of follow-up. High-dose rosuvastatin therapy resulted in a non-significant change of -1.4 mm3 (95% CI: -3.0, 0.1) in NC volume during follow-up (p=0.074). The change in NC percentage of total plaque volume was -1.4% (95% CI: -2.4 to -0.4; p=0.006). A neutral effect was also observed on LCBI. Indications of significant regression of NC volume and LCBI in the highest baseline quartiles were observed, which should cautiously be regarded as hypothesis-generating. CONCLUSIONS: High-intensity rosuvastatin therapy during one year resulted in a neutral effect on NC and LCBI within non-stenotic, non-culprit coronary segments with a relatively low atheroma burden. This study has been registered in The Netherlands Trial Register (NTR) nr. 2872.
Authors: Kohei Takata; Satoshi Honda; Samuel L Sidharta; MyNgan Duong; Daisuke Shishikura; Susan W Kim; Jordan Andrews; Belinda A Di Bartolo; Peter J Psaltis; Christina A Bursill; Matthew I Worthley; Stephen J Nicholls Journal: Cardiovasc Diagn Ther Date: 2019-08
Authors: Victor J van den Berg; Dorian O Haskard; Artur Fedorowski; Adam Hartley; Isabella Kardys; Mikhail Caga-Anan; K Martijn Akkerhuis; Rohit M Oemrawsingh; Robert Jan van Geuns; Peter de Jaegere; Nicolas van Mieghem; Evelyn Regar; Jurgen M R Ligthart; Victor A W M Umans; Patrick W Serruys; Olle Melander; Eric Boersma; Ramzi Y Khamis Journal: EBioMedicine Date: 2018-08-18 Impact factor: 8.143
Authors: Adam Mazurek; Krzysztof Gryga; Kamil Bugala; Teresa Iwaniec; Jacek Musial; Piotr Podolec; Wojciech Plazak Journal: Arch Med Sci Date: 2020-02-06 Impact factor: 3.318
Authors: Frans B Mensink; Tim J F Ten Cate; Sander A J Damen; Kit Roes; Carlo Di Mario; Varinder Singh; Ziad A Ali; William Skinner; Andre Artis; Rebecca Torguson; Cheng Zhang; Gheorghe Doros; Hector M Garcia-Garcia; Gary S Mintz; Robert-Jan van Geuns; Ron Waksman Journal: Int J Cardiol Heart Vasc Date: 2022-03-08